<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir is a nucleoside analog that can lead to lethal viral mutagenesis, chain termination or the inhibition of nucleotide biosynthesis [
 <xref rid="B70" ref-type="bibr">70</xref>]. Favipiravir in combination with oseltamivir, which was given to patients infected with SARS-CoV-2, has been used to treat severe influenza [
 <xref rid="B45" ref-type="bibr">45</xref>]. Oseltamivir, a neuraminidase inhibitor, is recommended as an antiviral treatment for influenza and has been widely used to inhibit COVID-19 in China [
 <xref rid="B45" ref-type="bibr">45</xref>,
 <xref rid="B70" ref-type="bibr">70</xref>]. Other neuraminidase inhibitors, zanamivir and peramivir, are also effective treatments for MERS-CoV [
 <xref rid="B71" ref-type="bibr">71</xref>]. At this time, these are all empirical therapies for COVID-19. However, whether oseltamivir or zanamivir are effective treatments for COVID-19 also needs further study.
</p>
